446284-38-4

Basic information

• Product Name: 1H-Pyrrolo[2,3-c]pyridine, 7-broMo-4-fluoro-
• Synonyms: 1H-Pyrrolo[2,3-c]pyridine, 7-broMo-4-fluoro-;7-BroMo-4-fluoro-6-azaindole;7-Bromo-4-fluoro-1H-pyrrolo[2,3-c]pyridine
• CAS NO: 446284-38-4
• Molecular Formula: C₇H₄BrFN₂
• Molecular Weight: 215.0224632
• Mol File: 446284-38-4.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1H-Pyrrolo[2,3-c]pyridine, 7-broMo-4-fluoro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-c]pyridine, 7-broMo-4-fluoro-(446284-38-4)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-c]pyridine, 7-broMo-4-fluoro-(446284-38-4)

Safety Data

• Hazardous Substances Data: 446284-38-4(Hazardous Substances Data)

Usage

Description

1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluorois a heterocyclic chemical compound characterized by a molecular formula of C9H5BrFN. It features a pyrrolopyridine ring with bromine and fluorine substituents, which endows it with unique structural and chemical properties. 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluoroholds promise in pharmaceuticals and medicinal chemistry due to its distinctive attributes, and it may be instrumental in the development of innovative drugs and therapeutics.

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluorois utilized as a key intermediate in the synthesis of new drugs and therapeutics. Its unique structure allows for the exploration of its potential in treating various diseases and conditions, making it a valuable asset in medicinal chemistry research and development.
Used in Organic Synthesis:
In the field of organic chemistry, 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluoroserves as a building block for the synthesis of other complex organic compounds. Its presence of bromine and fluorine atoms provides opportunities for further functionalization and modification, which can be applied across various industrial and research purposes to create novel molecules with specific properties and applications.

Upstream product

• 652160-72-0 2-bromo-5-fluoro-3-nitropyridine 
• 1826-67-1 vinyl magnesium bromide 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 51173-04-7 5-fluoro-2-methoxypyridine 
• 136888-20-5 5-fluoro-2-hydroxy-3-nitropyridine 
• 51173-05-8 5-fluoropyridin-2-ol 

Downstream Products

• 446284-50-0 4-fluoro-1H-pyrrolo[2,3-c]pyridine-7-carbonitrile 
• 446284-46-4 4-fluoro-1H-pyrrolo[2,3-c]pyridine-7-carbaldehyde 
• 959321-16-5 C₂₂H₂₀FN₅O₄ 
• 959321-17-6 C₂₁H₁₈FN₅O₄ 
• 446290-68-2 C₂₃H₁₈FN₅O₄ 
• 446290-66-0 C₂₃H₁₈FN₅O₄ 
• 446288-45-5 1-benzoyl-4-[(4-fluoro-7-(pyrazol-3-yl)-6-azaindol-3-yl)-oxoacetyl]piperazine 
• 619331-06-5 C₂₄H₂₀FN₇O₄ 
• 619331-08-7 C₂₅H₂₂FN₇O₄ 
• 619331-10-1 C₃₀H₃₁FN₈O₅ 
• 619331-09-8 C₂₆H₂₄FN₇O₄ 
• 619331-12-3 1-(4-benzoyl-piperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1H-pyrrolo[2,3-c]pyridin-3-yl)-ethane-1,2-dione 
• 619331-13-4 C₂₂H₁₈FN₇O₃ 
• 619331-11-2 C₂₂H₁₈FN₇O₃ 

Relevant articles and documents

Field-based affinity optimization of a novel azabicyclohexane scaffold HIV-1 entry inhibitor

Small-molecule HIV-1 entry inhibitors are an extremely attractive therapeutic modality. We have previously demonstrated that the entry inhibitor class can be optimized by using computational means to identify and extend the chemotypes available. Here we demonstrate unique and differential effects of previously published antiviral compounds on the gross structure of the HIV-1 Env complex, with an azabicyclohexane scaffolded inhibitor having a positive effect on glycoprotein thermostability. We demonstrate that modification of the methyltriazole-azaindole headgroup of these entry inhibitors directly effects the potency of the compounds, and substitution of the methyltriazole with an amine-oxadiazole increases the affinity of the compound 1000-fold over parental by improving the on-rate kinetic parameter. These findings support the continuing exploration of compounds that shift the conformational equilibrium of HIV-1 Env as a novel strategy to improve future inhibitor and vaccine design efforts.

Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents

This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with new aminium salts of 1,2,3-triazoles which can be used as prodrugs to improve

Prodrugs of piperazine and substituted piperidine antiviral agents

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.